Braidwell LP reported 78 positions worth $2.59B for the quarter ended Jun 30, 2026, up 7.8% on the prior quarter. It opened 20 new positions, added to 20, trimmed 34 and exited 19. Its largest holding is Caris Life Sciences, Inc. at 5.7% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| HUM Humana Inc | +114.5K | $45.48M | 1.76% |
| ATEC Alphatec Holdings, Inc. | +4.36M +200.6% | $37.70M | 2.18% |
| MAZE Maze Therapeutics, Inc. | +1.14M | $34.02M | 1.31% |
| AVTX Avalo Therapeutics, Inc. | +1.63M | $30.11M | 1.16% |
| ALMR Alamar Biosciences, Inc. | +1.08M | $29.37M | 1.13% |
| ORKA Oruka Therapeutics, Inc. | +278.2K | $26.47M | 1.02% |
| AVLN Avalyn Pharma Inc. | +801.4K | $26.38M | 1.02% |
| DMRA Damora Therapeutics, Inc. | +725.5K +81.1% | $18.87M | 1.63% |
| TMDX TransMedics Group, Inc. | +280.3K +85.1% | $18.62M | 1.56% |
| RGEN Repligen Corp | +129.6K +272.8% | $17.68M | 0.933% |
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| CGON CG Oncology, Inc. | -984.8K -100.0% | $66.65M | Exited |
| ARGX Argenx Se | -67.2K -79.2% | $62.38M | 0.635% |
| NBIX Neurocrine Biosciences Inc | -316.0K -48.4% | $53.25M | 2.19% |
| GH Guardant Health, Inc. | -351.9K -70.4% | $52.79M | 0.857% |
| MBX MBX Biosciences, Inc. | -781.6K -52.4% | $43.14M | 1.52% |
| PEN Penumbra Inc | -105.4K -100.0% | $34.59M | Exited |
| CLDX Celldex Therapeutics, Inc. | -919.4K -67.8% | $34.21M | 0.628% |
| DNTH Dianthus Therapeutics, Inc. | -304.8K -33.9% | $29.71M | 2.24% |
| BTSG BrightSpring Health Services, Inc. | -419.8K -41.3% | $29.28M | 1.61% |
| ILMN Illumina, Inc. | -229.2K -100.0% | $28.25M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| HUM Humana Inc | +114.5K | $45.48M | 1.76% |
| MAZE Maze Therapeutics, Inc. | +1.14M | $34.02M | 1.31% |
| AVTX Avalo Therapeutics, Inc. | +1.63M | $30.11M | 1.16% |
| ALMR Alamar Biosciences, Inc. | +1.08M | $29.37M | 1.13% |
| ORKA Oruka Therapeutics, Inc. | +278.2K | $26.47M | 1.02% |
| AVLN Avalyn Pharma Inc. | +801.4K | $26.38M | 1.02% |
| IMCR Immunocore Holdings plc | +521.3K | $16.55M | 0.639% |
| OVID Ovid Therapeutics Inc. | +5.92M | $15.92M | 0.615% |
| MNKD Mannkind Corp | +3.46M | $14.73M | 0.569% |
| QURE uniQure N.V. | +301.7K | $13.89M | 0.537% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| CGON CG Oncology, Inc. | -984.8K | $66.65M | 2.77% |
| PEN Penumbra Inc | -105.4K | $34.59M | 1.44% |
| ILMN Illumina, Inc. | -229.2K | $28.25M | 1.18% |
| BMRN Biomarin Pharmaceutical Inc | -497.0K | $28.08M | 1.17% |
| ESTA Establishment Labs Holdings Inc. | -463.6K | $26.32M | 1.1% |
| FULC Fulcrum Therapeutics, Inc. | -3.13M | $24.04M | 1% |
| CVS CVS HEALTH Corp | -290.7K | $20.88M | 0.869% |
| TARS Tarsus Pharmaceuticals, Inc. | -265.7K | $18.64M | 0.776% |
| ENGN enGene Therapeutics Inc. | -2.46M | $16.73M | 0.697% |
| TGTX Tg Therapeutics, Inc. | -358.8K | $11.92M | 0.496% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CAI Caris Life Sciences, Inc. | Healthcare | 8.26M | $147.12M | 5.68% | +246.6K | +3.1% | Added | 2.92% |
| 2 | HNGE Hinge Health, Inc. | Healthcare | 1.33M | $110.40M | 4.26% | -125.0K | -8.6% | Reduced | 1.65% |
| 3 | GKOS GLAUKOS Corp | Healthcare | 591.9K | $82.73M | 3.2% | -171.6K | -22.5% | Reduced | 1.01% |
| 4 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 2.00M | $81.14M | 3.13% | -350.6K | -14.9% | Reduced | 1.85% |
| 5 | SYRE Spyre Therapeutics, Inc. | Healthcare | 879.5K | $78.08M | 3.02% | -53.4K | -5.7% | Reduced | 1.04% |
| 6 | IRTC iRhythm Holdings, Inc. | Healthcare | 654.3K | $77.82M | 3.01% | +44.1K | +7.2% | Added | 1.99% |
| 7 | NEO Neogenomics Inc | Healthcare | 4.92M | $71.76M | 2.77% | -699.2K | -12.4% | Reduced | 3.79% |
| 8 | KOD Kodiak Sciences Inc. | Healthcare | 1.79M | $69.63M | 2.69% | -31.3K | -1.7% | Reduced | 2.84% |
| 9 | XENE Xenon Pharmaceuticals Inc. | Healthcare | 1.13M | $68.29M | 2.64% | -207.0K | -15.5% | Reduced | 1.14% |
| 10 | GLUE Monte Rosa Therapeutics, Inc. | Healthcare | 2.45M | $59.33M | 2.29% | -755.0K | -23.5% | Reduced | 2.42% |
| 11 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 594.6K | $57.96M | 2.24% | -304.8K | -33.9% | Reduced | 1.06% |
| 12 | NBIX Neurocrine Biosciences Inc | Healthcare | 336.2K | $56.66M | 2.19% | -316.0K | -48.4% | Reduced | 0.33% |
| 13 | ATEC Alphatec Holdings, Inc. | Healthcare | 6.53M | $56.50M | 2.18% | +4.36M | +200.6% | Added | 4.17% |
| 14 | GENB Generate Biomedicines, Inc. | Healthcare | 3.28M | $55.40M | 2.14% | -309.2K | -8.6% | Reduced | 2.56% |
| 15 | MRVI Maravai Lifesciences Holdings, Inc. | Healthcare | 8.70M | $54.31M | 2.1% | -1.54M | -15.0% | Reduced | 3.35% |
Tip. Select a row to see that position’s full history at Braidwell.
As of its Q2 2026 13F filing, Braidwell LP’s five largest positions were Caris Life Sciences, Inc. (CAI) at 5.7%, Hinge Health, Inc. (HNGE) at 4.3%, GLAUKOS Corp (GKOS) at 3.2%, Edgewise Therapeutics, Inc. (EWTX) at 3.1%, Spyre Therapeutics, Inc. (SYRE) at 3.0% of the reported portfolio.
Braidwell LP reported a 13F portfolio worth $2.59B across 78 positions for Q2 2026. That is up 7.8% from the previous quarter.
Its largest purchases by value were Humana Inc ($45.48M), Alphatec Holdings, Inc. ($37.70M), Maze Therapeutics, Inc. ($34.02M). It opened 20 new positions.
Its largest sales by value were CG Oncology, Inc. ($66.65M), Argenx Se ($62.38M), Neurocrine Biosciences Inc ($53.25M). It exited 19 positions entirely.
From the Form 13F-HR reports Braidwell LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.